Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

rNAPc2. Nuvelo.

Dennis Mungall1

  • 1College of Pharmacy, Ohio State University, 500 W Twelfth Ave, Columbus, OH 43210-1291, USA. Thertch@aol.com

Current Opinion in Investigational Drugs (London, England : 2000)
|April 16, 2004
PubMed
Summary

Recombinant nematode anticoagulant protein-2 (rNAPc2) is an antithrombotic protein investigated for cardiovascular diseases. Clinical trials were ongoing, but development for deep vein thrombosis was suspended.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BIBR-1048 Boehringer Ingelheim.

Current opinion in investigational drugs (London, England : 2000)·2002
See all related articles

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Recombinant nematode anticoagulant protein-2 (rNAPc2) is an antithrombotic agent.
  • rNAPc2 is under development as a therapeutic for acute cardiovascular diseases.

Purpose of the Study:

  • To evaluate rNAPc2 as a treatment for unstable angina and myocardial infarction.
  • To assess the efficacy and safety of rNAPc2 in clinical trials.

Main Methods:

  • Phase II clinical trials were conducted.
  • The study involved patients with major acute cardiovascular disease.

Main Results:

  • Phase II clinical trials for cardiovascular indications were ongoing as of January 2004.
  • Development for deep vein thrombosis was suspended due to the need for a partner.

Conclusions:

  • rNAPc2 shows potential for treating acute cardiovascular diseases.
  • Further development and partnerships are required for deep vein thrombosis applications.

Related Experiment Videos